Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
McKessonMEX:MCK 73 Return-on-Tangible-Asset is 9.93% as of Mar. 2026, which is 159% above its 10-year median of 3.84. GuruFocus rates MEX:MCK with a GF Score™ of 73/100 and a GF Value™ of MXN13,309.60 (Fairly Valued). The stock has 2 warning signs investors should review. Among 118 Medical Distribution companies, McKesson ranks better than 82.2% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. McKesson's annualizedNet Income for the quarter that ended in Mar. 2026 was MXN121,324 Mil. McKesson's average total tangible assets for the quarter that ended in Mar. 2026 was MXN1,221,825 Mil. Therefore, McKesson's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 9.93%.
The historical rank and industry rank for McKesson's Return-on-Tangible-Asset or its related term are showing as below:
MEX:MCK'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -8.95 Med: 3.84 Max: 11.21
Current: 7.14
During the past 13 years, McKesson's highest Return-on-Tangible-Asset was 11.21%. The lowest was -8.95%. And the median was 3.84%.
MEX:MCK's Return-on-Tangible-Asset is ranked better than 82.2% of 118
companies
in the Medical Distribution industry
Industry Median: 2.34
vs MEX:MCK: 7.14
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
McKesson Return-on-Tangible-Asset Related Terms
McKesson Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for McKesson's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:MCK vs CAH, COR, HSIC: Return-on-Tangible-Asset Comparison
For the Medical Distribution subindustry, McKesson's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
McKesson Return-on-Tangible-Asset vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, McKesson's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where McKesson's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 9.93% mean?
McKesson (MEX:MCK) has a Return-on-Tangible-Asset of 9.93% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on McKesson and its competitors. This is 159% above median its historical median of 3.84. According to the industry distribution chart, McKesson ranks #21 out of 118 companies in the Medical Distribution industry, placing it in the top 17.8%.
Is McKesson's Return-on-Tangible-Asset too high?
McKesson's current Return-on-Tangible-Asset of 9.93% is 159% above median its 10-year median of 3.84. The Medical Distribution industry median Return-on-Tangible-Asset is 2.34. McKesson's value of 9.93% is 324.4% above this industry median. Based on the distribution chart, McKesson ranks #21 out of 118 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, McKesson has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does McKesson's Return-on-Tangible-Asset compare to CAH and COR?
According to the Medical Distribution industry distribution chart, McKesson ranks #21 out of 118 companies for Return-on-Tangible-Asset. This places McKesson in the top 18% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 2.34. McKesson's value of 9.93% is 324.4% above this benchmark. While the company's 10-year median is 3.84 vs. the industry median of 2.34, McKesson has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Distribution company?
The median Return-on-Tangible-Asset among Medical Distribution companies is 2.34, based on 118 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. McKesson's current Return-on-Tangible-Asset of 9.93% is 324.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on McKesson and its competitors. For the Medical Distribution industry, the median Return-on-Tangible-Asset is 2.34 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. McKesson's current Return-on-Tangible-Asset is 9.93%, which is 159% above median its own 10-year median of 3.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is McKesson stock overvalued right now?
Based on GuruFocus' analysis, McKesson (MEX:MCK) is currently considered Fairly Valued. The stock's GF Value™ is MXN13,309.60, compared to a current price of MXN14,083.59 — trading 5.8% above its estimated fair value. The current Return-on-Tangible-Asset is 9.93%, which is 159% above median its 10-year median of 3.84 and 324.4% above the Medical Distribution industry median of 2.34. McKesson's overall GF Score™ is 73/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For McKesson (MEX:MCK), the current Return-on-Tangible-Asset is 9.93% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is McKesson (MEX:MCK) Overvalued in 2026?
Based on GuruFocus' analysis, McKesson stock appears to be overvalued.
The current stock price of MXN14,083.59 is trading 5.8% above its estimated GF Value™ of MXN13,309.60.
GuruFocus considers McKesson to be Fairly Valued.
Key valuation signals for MEX:MCK:
Return-on-Tangible-Asset: 9.93% (159% above median its 10-year median of 3.84)
GF Value™: MXN13,309.60 vs. price of MXN14,083.59 (5.8% above fair value)
Industry Position: 324.4% above the Medical Distribution median (#21 of 118)
No single metric tells the full story. See the MEX:MCK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
McKesson is one of three leading pharmaceutical wholesalers in the US engaged in sourcing and distributing branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with Cencora and Cardinal Health, the three account for over 90% of the US pharmaceutical wholesale industry. Outside the US market, McKesson engages in pharmaceutical wholesale and distribution in Canada. Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
73GF Score
Get the complete analysis for MEX:MCK
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:MCK has been successfully added to your 
